vs
BayCom Corp（BCML）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是BayCom Corp的1.2倍（$30.3M vs $25.9M），BayCom Corp净利率更高（26.5% vs -221.3%，领先247.8%），REGENXBIO Inc.同比增速更快（43.0% vs 9.4%），BayCom Corp自由现金流更多（$30.1M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 2.9%）
BayCom Corp是总部位于美国的银行控股公司，旗下拥有海湾商业银行，主要服务北加州地区的中小微企业与零售客户，提供商业贷款、存款产品、个人银行、财富管理等多元金融服务，深耕本土社区金融市场。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
BCML vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.2倍
$25.9M
营收增速更快
RGNX
高出33.6%
9.4%
净利率更高
BCML
高出247.8%
-221.3%
自由现金流更多
BCML
多$82.9M
$-52.8M
两年增速更快
RGNX
近两年复合增速
2.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $25.9M | $30.3M |
| 净利润 | $6.9M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 36.6% | -190.0% |
| 净利率 | 26.5% | -221.3% |
| 营收同比 | 9.4% | 43.0% |
| 净利润同比 | 12.1% | -31.2% |
| 每股收益（稀释后） | $0.63 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BCMLRGNX
| Q4 25 | $25.9M | $30.3M | ||
| Q3 25 | $25.7M | $29.7M | ||
| Q2 25 | $24.7M | $21.4M | ||
| Q1 25 | $24.3M | $89.0M | ||
| Q4 24 | $23.7M | $21.2M | ||
| Q3 24 | $25.6M | $24.2M | ||
| Q2 24 | $23.8M | $22.3M | ||
| Q1 24 | $24.5M | $15.6M |
净利润BCMLRGNX
| Q4 25 | $6.9M | $-67.1M | ||
| Q3 25 | $5.0M | $-61.9M | ||
| Q2 25 | $6.4M | $-70.9M | ||
| Q1 25 | $5.7M | $6.1M | ||
| Q4 24 | $6.1M | $-51.2M | ||
| Q3 24 | $6.0M | $-59.6M | ||
| Q2 24 | $5.6M | $-53.0M | ||
| Q1 24 | $5.9M | $-63.3M |
毛利率BCMLRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率BCMLRGNX
| Q4 25 | 36.6% | -190.0% | ||
| Q3 25 | 26.3% | -176.3% | ||
| Q2 25 | 35.3% | -296.3% | ||
| Q1 25 | 31.6% | 13.6% | ||
| Q4 24 | 34.2% | -242.1% | ||
| Q3 24 | 32.4% | -256.6% | ||
| Q2 24 | 31.9% | -251.3% | ||
| Q1 24 | 33.3% | -408.8% |
净利率BCMLRGNX
| Q4 25 | 26.5% | -221.3% | ||
| Q3 25 | 19.5% | -208.3% | ||
| Q2 25 | 25.8% | -331.8% | ||
| Q1 25 | 23.4% | 6.8% | ||
| Q4 24 | 25.9% | -241.3% | ||
| Q3 24 | 23.5% | -246.3% | ||
| Q2 24 | 23.6% | -237.7% | ||
| Q1 24 | 24.0% | -405.4% |
每股收益（稀释后）BCMLRGNX
| Q4 25 | $0.63 | $-1.30 | ||
| Q3 25 | $0.46 | $-1.20 | ||
| Q2 25 | $0.58 | $-1.38 | ||
| Q1 25 | $0.51 | $0.12 | ||
| Q4 24 | $0.55 | $-0.99 | ||
| Q3 24 | $0.54 | $-1.17 | ||
| Q2 24 | $0.50 | $-1.05 | ||
| Q1 24 | $0.51 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $338.6M | $102.7M |
| 总资产 | $2.6B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BCMLRGNX
| Q4 25 | — | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M | ||
| Q1 24 | — | $338.7M |
股东权益BCMLRGNX
| Q4 25 | $338.6M | $102.7M | ||
| Q3 25 | $334.3M | $161.5M | ||
| Q2 25 | $330.6M | $213.7M | ||
| Q1 25 | $329.3M | $274.2M | ||
| Q4 24 | $324.4M | $259.7M | ||
| Q3 24 | $321.7M | $301.4M | ||
| Q2 24 | $315.3M | $348.3M | ||
| Q1 24 | $314.2M | $390.7M |
总资产BCMLRGNX
| Q4 25 | $2.6B | $453.0M | ||
| Q3 25 | $2.6B | $525.2M | ||
| Q2 25 | $2.6B | $581.0M | ||
| Q1 25 | $2.6B | $490.9M | ||
| Q4 24 | $2.7B | $466.0M | ||
| Q3 24 | $2.6B | $519.1M | ||
| Q2 24 | $2.6B | $569.4M | ||
| Q1 24 | $2.6B | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $31.8M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $30.1M | $-52.8M |
| 自由现金流率自由现金流/营收 | 116.2% | -174.0% |
| 资本支出强度资本支出/营收 | 6.7% | 1.7% |
| 现金转化率经营现金流/净利润 | 4.64× | — |
| 过去12个月自由现金流最近4个季度 | $51.1M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流BCMLRGNX
| Q4 25 | $31.8M | $-52.3M | ||
| Q3 25 | $7.3M | $-56.0M | ||
| Q2 25 | $6.4M | $-49.3M | ||
| Q1 25 | $9.3M | $33.6M | ||
| Q4 24 | $30.4M | $-31.6M | ||
| Q3 24 | $9.6M | $-40.5M | ||
| Q2 24 | $7.7M | $-45.5M | ||
| Q1 24 | $5.1M | $-55.5M |
自由现金流BCMLRGNX
| Q4 25 | $30.1M | $-52.8M | ||
| Q3 25 | $6.2M | $-56.5M | ||
| Q2 25 | $5.6M | $-49.7M | ||
| Q1 25 | $9.1M | $32.6M | ||
| Q4 24 | $28.7M | $-32.7M | ||
| Q3 24 | $9.4M | $-40.9M | ||
| Q2 24 | $7.4M | $-46.0M | ||
| Q1 24 | $3.9M | $-56.0M |
自由现金流率BCMLRGNX
| Q4 25 | 116.2% | -174.0% | ||
| Q3 25 | 24.3% | -189.9% | ||
| Q2 25 | 22.8% | -232.8% | ||
| Q1 25 | 37.6% | 36.6% | ||
| Q4 24 | 121.1% | -154.2% | ||
| Q3 24 | 36.6% | -168.9% | ||
| Q2 24 | 31.2% | -206.2% | ||
| Q1 24 | 16.1% | -358.5% |
资本支出强度BCMLRGNX
| Q4 25 | 6.7% | 1.7% | ||
| Q3 25 | 4.3% | 1.7% | ||
| Q2 25 | 3.0% | 1.8% | ||
| Q1 25 | 0.6% | 1.2% | ||
| Q4 24 | 7.2% | 5.1% | ||
| Q3 24 | 1.0% | 1.3% | ||
| Q2 24 | 1.0% | 2.1% | ||
| Q1 24 | 4.7% | 3.6% |
现金转化率BCMLRGNX
| Q4 25 | 4.64× | — | ||
| Q3 25 | 1.47× | — | ||
| Q2 25 | 1.00× | — | ||
| Q1 25 | 1.63× | 5.53× | ||
| Q4 24 | 4.96× | — | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.37× | — | ||
| Q1 24 | 0.86× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BCML
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
